Key Insights

Highlights

Treatment Research

1 treatments under study, led by Cg001419 Tablets

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07394374Phase 1/2Recruiting

A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

Showing all 1 trials

Research Network

Common Treatments

  • Cg001419 Tablets1

Active Sponsors

  • Cullgen (Shanghai),Inc1

Top Investigators

  • Ning Li, MD1

    The Cancer Hospital, Chinese Academy of Medical Sciences

Related Conditions

  • Ntrk1
  • Solid Tumors Harboring Ntrk Fusion1
  • Ntrk Fusion Positive1

Activity Timeline